Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

[Research on network pharmacology of alkaloids in Sophora alopecuroides].

Shang BY, Yang P, Chen L, Gao XJ, Yong JJ, Zhang X, Zhao JJ, Wang HQ.

Zhongguo Zhong Yao Za Zhi. 2018 Jan;43(1):160-167. doi: 10.19540/j.cnki.cjcmm.20171027.017. Chinese.

PMID:
29552827
2.

A new HDAC inhibitor cinnamoylphenazine shows antitumor activity in association with intensive macropinocytosis.

Zhu BY, Shang BY, Du Y, Li Y, Li L, Xu XD, Zhen YS.

Oncotarget. 2017 Feb 28;8(9):14748-14758. doi: 10.18632/oncotarget.14714.

3.

A recombinantly tailored β-defensin that displays intensive macropinocytosis-mediated uptake exerting potent efficacy against K-Ras mutant pancreatic cancer.

Du Y, Shang BY, Sheng WJ, Zhang SH, Li Y, Miao QF, Zhen YS.

Oncotarget. 2016 Sep 6;7(36):58418-58434. doi: 10.18632/oncotarget.11170.

4.

A Novel Nitrobenzoate Microtubule Inhibitor that Overcomes Multidrug Resistance Exhibits Antitumor Activity.

Zheng YB, Gong JH, Liu XJ, Wu SY, Li Y, Xu XD, Shang BY, Zhou JM, Zhu ZL, Si SY, Zhen YS.

Sci Rep. 2016 Aug 11;6:31472. doi: 10.1038/srep31472.

5.
6.

Genetically engineered endostatin-lidamycin fusion proteins effectively inhibit tumor growth and metastasis.

Jiang WG, Lu XA, Shang BY, Fu Y, Zhang SH, Zhou D, Li L, Li Y, Luo Y, Zhen YS.

BMC Cancer. 2013 Oct 15;13:479. doi: 10.1186/1471-2407-13-479.

7.

Bortezomid enhances the efficacy of lidamycin against human multiple myeloma cells.

Zhen YZ, Lin YJ, Liu XJ, Shang BY, Zhen YS.

Anticancer Drugs. 2013 Jul;24(6):609-16. doi: 10.1097/CAD.0b013e3283615006.

PMID:
23698252
8.

An NGR-integrated and enediyne-energized apoprotein shows CD13-targeting antitumor activity.

Zheng YB, Shang BY, Li Y, Zhen YS.

Biomed Pharmacother. 2013 Mar;67(2):164-71. doi: 10.1016/j.biopha.2012.10.018. Epub 2012 Nov 19.

PMID:
23206754
9.

A cell penetrating peptide-integrated and enediyne-energized fusion protein shows potent antitumor activity.

Ru Q, Shang BY, Miao QF, Li L, Wu SY, Gao RJ, Zhen YS.

Eur J Pharm Sci. 2012 Nov 20;47(4):781-9. doi: 10.1016/j.ejps.2012.09.002. Epub 2012 Sep 13.

PMID:
22982402
10.

[Lidamycin inhibits the proliferation of HERG K+ channel highly expressing cancer cells and shows synergy with anticancer drugs].

Shang BY, Shang Y, Zhen YS, Chen SZ.

Yao Xue Xue Bao. 2011 Nov;46(11):1321-5. Chinese.

PMID:
22260022
11.

Endostar, a modified recombinant human endostatin, exhibits synergistic effects with dexamethasone on angiogenesis and hepatoma growth.

Li XQ, Shang BY, Wang DC, Zhang SH, Wu SY, Zhen YS.

Cancer Lett. 2011 Feb 28;301(2):212-20. doi: 10.1016/j.canlet.2010.12.004. Epub 2011 Jan 7.

PMID:
21216091
12.

HERG K+ channel related chemosensitivity to sparfloxacin in colon cancer cells.

Gong JH, Liu XJ, Shang BY, Chen SZ, Zhen YS.

Oncol Rep. 2010 Jun;23(6):1747-56.

PMID:
20428834
13.

Rhein lysinate suppresses the growth of tumor cells and increases the anti-tumor activity of Taxol in mice.

Lin YJ, Zhen YZ, Shang BY, Zhen YS.

Am J Chin Med. 2009;37(5):923-31.

PMID:
19885952
14.

Enediyne lidamycin induces apoptosis in human multiple myeloma cells through activation of p38 mitogen-activated protein kinase and c-Jun NH2-terminal kinase.

Zhen YZ, Lin YJ, Shang BY, Zhen YS.

Int J Hematol. 2009 Jul;90(1):44-51. doi: 10.1007/s12185-009-0340-3. Epub 2009 May 26.

PMID:
19468799
15.

[Antitumor activities of various immunoconjugates composed of lidamycin and anti-type IV collagenase monoclonal antibody].

Feng Y, Zhen YS, Dai Y, Shang BY, Zhang M, He HW, Li BW, Shao RG.

Yao Xue Xue Bao. 2007 Jul;42(7):704-9. Chinese.

PMID:
17882952
16.

An enediyne-energized single-domain antibody-containing fusion protein shows potent antitumor activity.

Miao QF, Liu XY, Shang BY, Ouyang ZG, Zhen YS.

Anticancer Drugs. 2007 Feb;18(2):127-37.

PMID:
17159599
17.

Antitumor activity of anti-type IV collagenase monoclonal antibody and its lidamycin conjugate against colon carcinoma.

Li L, Huang YH, Li Y, Wang FQ, Shang BY, Zhen YS.

World J Gastroenterol. 2005 Aug 7;11(29):4478-83.

18.

Antitumor efficacy of lidamycin on hepatoma and active moiety of its molecule.

Huang YH, Shang BY, Zhen YS.

World J Gastroenterol. 2005 Jul 14;11(26):3980-4.

19.

Silencing of hdm2 oncogene by siRNA inhibits p53-dependent human breast cancer.

Liu TG, Yin JQ, Shang BY, Min Z, He HW, Jiang JM, Chen F, Zhen YS, Shao RG.

Cancer Gene Ther. 2004 Nov;11(11):748-56.

PMID:
15375377
20.

[Immunoscintigraphy of anti-type IV collagenase monoclonal antibody in nude mice bearing human lung cancer xenograft].

Dai Y, Jia B, Wang F, Du J, Shang BY, Zhen YS.

Ai Zheng. 2003 Dec;22(12):1243-8. Chinese.

PMID:
14693044
21.

[Antitumor effects of the immunoconjugate composed of lidamycin and monoclonal antibody 3G11].

Wang FQ, Shang BY, Zhen YS.

Yao Xue Xue Bao. 2003 Jul;38(7):515-9. Chinese.

PMID:
14515796
22.

Antitumor components from an actinomycete strain 6011W.

Jiang XF, Shang BY, Jin LF, Hu JL, Zhen YS.

J Asian Nat Prod Res. 1999;2(1):31-8.

PMID:
11261203
23.

Supplemental Content

Loading ...
Support Center